ReviewDrugs2004
Moxifloxacin: a review of its use in the management of bacterial infections.
Review in Drugs, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- Meta-analysis on Effectiveness and Safety of Moxifloxacin in Treatment of Multidrug Resistant Tuberculosis in Adults.Medicine · 2020Pooled it
- The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2013Pooled it
- Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.World journal of gastroenterology · 2015Trial
- Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial.Annals of clinical microbiology and antimicrobials · 2010Trial
- Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.Wiener klinische Wochenschrift · 2009Trial
- Comparative efficacies of amoxicillin, clindamycin, and moxifloxacin in prevention of bacteremia following dental extractions.Antimicrobial agents and chemotherapy · 2006Trial
- Eco-friendly approach for spectrofluorimetric determination of moxifloxacin in pharmaceutical formulations and biological samples using deep eutectic solvents.BMC chemistry · 2026Article
- Do Aminopenicillins Have a Role in Treating Ampicillin-ResistantOpen forum infectious diseases · 2025Article
- Prediction of Human Microbe-Drug Association based on Layer Attention Graph Convolutional Network.Current medicinal chemistry · 2024Article
- Greener and Whiter Analytical Chemistry Using Cyrene as a More Sustainable and Eco-Friendlier Mobile Phase Constituent in Chromatography.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Corneal foreign bodies: are antiseptics and antibiotics equally effective?Eye (London, England) · 2023Article
- Colon-Targeted Layer-by-Layer Self-assembled Film: Pharmacokinetic Analysis of BCS Class I and Class III Model Drugs.AAPS PharmSciTech · 2022Article
- Implementation of HILIC-UV technique for the determination of moxifloxacin and fluconazole in raw materials and pharmaceutical eye gel.Scientific reports · 2022Article
- Potential new fluoroquinolone treatments for suspected bacterial keratitis.BMJ open ophthalmology · 2022Review
- The Effect of Conjugation of Ciprofloxacin and Moxifloxacin with Fatty Acids on Their Antibacterial and Anticancer Activity.International journal of molecular sciences · 2022Article
- The Mycobacterial Efflux Pump EfpA Can Induce High Drug Tolerance to Many Antituberculosis Drugs, Including Moxifloxacin, in Mycobacterium smegmatis.Antimicrobial agents and chemotherapy · 2021Article
- Fabrication of Antimicrobial Multilayered Nanofibrous Scaffolds-Loaded DrugFrontiers in bioengineering and biotechnology · 2021Article
- Topoisomerase II as a target for repurposed antibiotics inIn silico pharmacology · 2021Review
- Simultaneous Determination of Moxifloxacin and Flavoxate by RP-HPLC and Ecofriendly Derivative Spectrophotometry Methods in Formulations.International journal of environmental research and public health · 2019Article
- Can systemically administered antibiotics be detected in wound tissues and surfaces under negative pressure wound therapy?International wound journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moxifloxacin (Avelox) is a fluoroquinolone antibacterial with a methoxy group in the C-8 position and a bulky C-7 side chain. Moxifloxacin is approved for use in the treatment of acute exacerbations of chronic bronchitis (AECB), community-acquired pneumonia (CAP), acute bacterial sinusitis and uncomplicated skin and skin structure infections (approved indications may differ between countries). Moxifloxacin has a broad spectrum of antibacterial activity, including activity against penicillin-resistant Streptococcus pneumoniae. It achieves good tissue penetration and has a convenient once-daily administration schedule, as well as being available in both intravenous and oral formulations in some markets. Moxifloxacin has good efficacy in the treatment of patients with AECB, CAP, acute bacterial sinusitis and uncomplicated skin and skin structure infections, and is generally well tolerated. Thus, moxifloxacin is an important option in the treatment of bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.